↑ トップへ ← 戻る

 Drug(薬物リスト) ALL | DrugBank 

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

74 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   Abatacept  27件: Abatacept; Abatacept injection; Bms 188667 (abatacept); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (iv); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept placebo; Abatacept prefilled syringe; Abatacept, rituximab or tocilizumab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Decrease tocilizumab, abatacept; Double-blind abatacept; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept; Abatacept subcutaneous; Abatacept sc; Abatacept (aba);   D03203   2件: CD80, CD86   3件: Cell adhesion molecules (CAMs), Intestinal immune network for IgA production, Rheumatoid arthritis   24件:
11,
13,
19,
41,
44,
46,
49,
50,
51,
53,
55,
60,
65,
84,
93,
96,
97,
107,
164,
222,
271,
284,
285,
300
 2   Adalimumab  51件: Adalimumab; Adalimumab injection [humira]; Adalimumab (ada); Adalimumab (humira); Adalimumab (humira®); Adalimumab (up to 9 months exposure); Adalimumab 40 mg; Adalimumab 40 mg subcutaneous (sc) every other week (eow); Adalimumab 40mg q2w; Adalimumab 80 mg; Adalimumab pfs and pen; Adalimumab with methotrexate; Adalimumab-eu; Adalimumab-pfizer; Anti-tnf therapy (etanercept or adalimumab); Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar product to adalimumab; Double-blind adalimumab; Etanercept or adalimumab; Humira (adalimumab); Humira 40mg solution for injection in pre-filled syringe (adalimumab); Humira® (adalimumab); Infliximab, etanercept, adalimumab; Methotrexate,adalimumab; New formulation adalimumab; Open-label adalimumab; Open-labeladalimumabrescue; Sb5 (proposed biosimilar to adalimumab); Tnf blockers (infliximab, adalimumab, etanercept); Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Adalimumab (40 mg); Adalimumab (d2e7); Adalimumab 40 mg eow or ew; Adalimumab and infliximab; Adalimumab injection; Adalimumab prn; Anti-tnf:adalimumab (subcutaneus); Application of adalimumab; Azathioprine or adalimumab and infliximab; Db adalimumab 40 mg eow; Db adalimumab 40 mg ew; Fitc-adalimumab; Infliximab and adalimumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab, adalimumab, certolizumab pegol; Ol adalimumab 40 mg; Start adalimumab in monotherapy; Treatment with adalimumab; Adalimumab 40 mg sc every other week; Adalimumab, etanercept, golimumab or infliximab; Gp2017 (adalimumab biosimilar);   D02597   1件: TNF   9件: Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   15件:
19,
37,
41,
46,
56,
84,
96,
97,
151,
160,
164,
222,
226,
269,
271
 3   Ademetionine  0件:   D07128   -   -   15件:
6,
14,
22,
43,
44,
46,
47,
49,
50,
60,
84,
93,
96,
97,
172
 4   Ambrisentan  8件: Ambrisentan; Tadalafil and ambrisentan upfront combination therapy; Ambrisentan - high dose; Ambrisentan - low dose; Ambrisentan 5 mg film-coated tablets; Ambrisentan plus spironolactone; Bosentan, ambrisentan; Ambrisentan 5 mg;   D07077   1件: EDNRA   2件: Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction   6件:
51,
84,
85,
86,
88,
211
 5   Anakinra  8件: Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra and peg stnf-r1; Kineret® (anakinra); Response to anakinra associated with methotrexate; Anakinra / kineret; Kineret® or anakinra;   D02934   2件: IL1R1, IL1R2   2件: Cytokine-cytokine receptor interaction, Inflammatory mediator regulation of TRP channels   17件:
2,
13,
15,
19,
37,
41,
46,
49,
50,
56,
65,
84,
86,
106,
107,
266,
299
 6   Armodafinil  1件: Armodafinil;   D03215   1件: SLC6A3   1件: Dopaminergic synapse   3件:
6,
13,
84
 7   Atorvastatin  9件: Atorvastatin; Interferon beta treatment to add-on atorvastatin treatment; Interferon beta-1b/atorvastatin group; Untreated to atorvastatin treatment; Atorvastatin tablet 20 mg; Atorvastatin 10mg; Atorvastatin 20mg; Lisinopril, losartan, and atorvastatin; Atorvastatin calcium;   D00258
 D00887
 D07474 
 1件: HMGCR   1件: Terpenoid backbone biosynthesis   17件:
13,
46,
49,
51,
58,
63,
79,
84,
88,
93,
96,
160,
222,
225,
265,
271,
299
 8   Azithromycin  12件: Azithromycin; Azithromycin 250mg capsule; Azithromycin + metronidazole; Azithromycin (zitromax°); Azithromycin + n-acetylcystein + inhaled corticosteroid; Azithromycin dihydrate; Azithromycine; Azithromycine 250 mg; Azithromycin 250 mg tablets; Azithromycin 500 mg film-coated tablet; Po azithromycin; Study medication, azithromycin;   D02134
 D06390
 D07486 
 -   -   6件:
13,
84,
85,
96,
228,
299
 9   Bardoxolone  4件: Bardoxolone; Bardoxolone methyl; Bardoxolone methyl capsules; Bardoxolone methyl oral capsule;   D09584   -   -   7件:
66,
67,
84,
85,
86,
218,
222
 10   Bardoxolone methyl  3件: Bardoxolone methyl; Bardoxolone methyl capsules; Bardoxolone methyl oral capsule;   D09585   -   -   7件:
66,
67,
84,
85,
86,
218,
222
 11   Bosentan  14件: Bosentan; Bosentan mylan; Bosentan (tracleer); Bosentan 125 mg; Bosentan 62.5 mg; Bosentan group; Bosentan monohydrate; Sildenafil 20mg and bosentan 62.5mg; Bosentan administration; Bosentan and sildenafil; Bosentan monohydrat; Bosentan, ambrisentan; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Sildenafil singly or in association with bosentan;   D01227
 D07538 
 2件: EDNRA, EDNRB   2件: Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction   10件:
13,
41,
47,
51,
84,
85,
86,
88,
210,
211
 12   CC-220  3件: Cc-220; Cc-220 0.3 mg daily; Cc-220 0.6mg daily;   -   -   -   2件:
49,
84
 13   Calcium  26件: Calcium; Calcium carbonate; Calcium levofolinate; Ascal(r) / carbasalate calcium; Calcium and cholecalciferol; Calcium citrate; Carbasalate calcium; Ethylhydrogenfumarat, calciumsalz; Ibandronate+alfacalcidol+calcium; Rosuvastatin calcium; Calcium channel blockers; Calcium channel blockers (amlodipine, azelnidipine); Calcium rosuvastatin; Crestor tablets (calcium rosuvastatin) film-coated tablets; Calcium citrate with vitamin d2; Vidofludimus calcium; Calcium gluconate; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin); Low molecular weight heparin calcium injection; Amorphous calcium carbonate; Calcitriol & calcium; Calcium carbonate and alphacalcidol; Calcium lactate; Crystalline calcium supplements; Atorvastatin calcium; Calcium, dietary;   -   -   -   24件:
6,
13,
19,
46,
49,
51,
65,
68,
75,
79,
84,
93,
94,
95,
96,
97,
214,
215,
222,
224,
235,
265,
298,
299
 14   Calcium Citrate  2件: Calcium citrate; Calcium citrate with vitamin d2;   D00933   -   -   3件:
46,
84,
235
 15   Canakinumab  7件: Canakinumab; Canakinumab (investigational); Canakinumab (proposed); Canakinumab (acz885); Canakinumab (company code: acz885d); Canakinumab (who approval pending); Canakinumab injection [ilaris];   D09315   1件: IL1B   3件: Cytokine-cytokine receptor interaction, MAPK signaling pathway, NOD-like receptor signaling pathway   9件:
46,
56,
84,
106,
107,
108,
113,
266,
269
 16   Ciclesonide  1件: Ciclesonide;   D01703   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
84
 17   Clarithromycin  6件: Clarithromycin; Lansoprazole, clarithromycin, amoxycillin; Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication); Rifabutin, clarithromycin, and clofazimine; Lansoprazole, amoxicillin, clarithromycin; Biaxin ( clarithromycin);   D00276   -   -   8件:
6,
63,
84,
96,
97,
222,
228,
299
 18   Corticotropin  10件: Corticotropin; Repository corticotropin injection; H.p. acthar gel (repository corticotropin injection); H.p. acthar® gel (repository corticotropin injection); Corticotropin-releasing hormone; Ovine corticotropin-releasing hormone (ocrh); Corticotropin releasing hormone; Repository corticotropin injection -treatment extension; Adrenocorticotropin; Adrenocorticotropin hormone;   D00146   1件: MC2R   3件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Neuroactive ligand-receptor interaction   12件:
2,
13,
46,
49,
50,
66,
75,
78,
84,
145,
193,
222
 19   Cyclophosphamide  49件: Cyclophosphamide; Cyclophosphamide (drug); Cyclophosphamide and atg; Cyclophosphamide monohydrate; Cyclophosphamide/glatiramer acetate; Busulfan, cyclophosphamide, antithymocyte globulin; Busulfan, cyclophosphamide, atg; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Lenalidomide, dexamethasone and cyclophosphamide; Rituximab and cyclophosphamide iv; Prednisone, cyclophosphamide; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Cyclophosphamide-prednisone-azathioprine; Iv cyclophosphamide; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Cyclophosphamide (cy); Cyclophosphamide (cy) (plan 1); Cyclophosphamide (cy) (plan 2); Cyclophosphamide 100mg; Cyclophosphamide 150mg; Cyclophosphamide 50mg; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Cyclophosphamide,campath ih and tbi; Cyclophosphamide,cyclosporine a; Fludarabine, cyclophosphamide; Haploidentical hsct using tbi free regimen, ''atg'' with ''post transplant cyclophosphamide''; Busulfan, cyclophosphamide, atg, gcsf; Campath, fludarabine, cyclophosphamide; Cyclophosphamide 30; Cyclophosphamide 40; Cyclophosphamide dose level 1; Cyclophosphamide dose level 2; Cyclophosphamide dose level 3; Cyclophosphamide dose level 4; Cyclophosphamide post transplant; Prednisone and cyclophosphamide; Prednisone plus cyclophosphamide; High-dose cyclophosphamide; Cyclophosphamide 50mg oral tablet; Cyclophosphamide and steroids; Cyclophosphamide(ctx); Cyclophosphamide + pred; Cyclophosphamide, fludarabine; Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Thalidomide, cyclophosphamide and prednisone;   D00287
 D07760 
 -   -   43件:
13,
14,
16,
19,
20,
26,
28,
35,
36,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
52,
56,
60,
61,
62,
65,
66,
84,
85,
93,
96,
162,
164,
172,
222,
224,
265,
274,
283,
284,
285,
288,
326,
331
 20   Dapsone  1件: Dapsone;   D00592   -   -   4件:
35,
42,
60,
84
 21   Dexamethasone  35件: Dexamethasone; Dexamethasone soduim phosphate; Lenalidomide and dexamethasone; Lenalidomide+dexamethasone; Lenalidomide, dexamethasone; Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Dexamethasone, 40 mg; Lenalidomide, dexamethasone and cyclophosphamide; Melphalan, thalidomide and dexamethasone; Pomalidomide and dexamethasone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Dexamethasone (50mg 1dd6, 3 consecutive days/month); Control intervention (no dexamethasone); Intraarticular dexamethasone; Intravenous dexamethasone 1 mg; Peri-neural dexamethasone 1 mg; Dexamethasone parotid irrigation; Dexamethasone (1 cycle); Dexamethasone (4 cycles); Dexamethasone abcur; Dexamethasone and rituximab; High dose dexamethasone pulses; Dexamethasone sodium phosphate; Dexamethasone sodium phosphate ph. eur.; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Dexamethasone 0.5mg tablet; Dexamethasone 2mg tablets; Dexamethasone 0,5mg; Bupivacaine/epinephrine/dexamethasone; Dexamethasone sodium phosphate 250 mg/ 10 ml; Dexamethasone 21-phosphate; Mmf and dexamethasone; Dexamethasone sodium phosphate 250 mg/10 ml solution;   D00292
 D00975
 D01510
 D01615
 D01632
 D01948
 D02174
 D02591
 D02592 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   20件:
13,
16,
28,
35,
46,
53,
63,
65,
70,
74,
75,
81,
83,
84,
90,
96,
97,
222,
296,
299
 22   Dotatate  6件: Dotatate; Dotatate pet-ct; 68ga-dotatate; 68ga-dotatate pet/ct; Cu-64 dotatate; Gallium-68 dotatate;   -   -   -   3件:
41,
75,
84
 23   Dotatate gallium Ga-68  0件:   -   -   -   1件:
84
 24   Doxycycline  7件: Doxycycline; Interferon beta 1a, oral doxycycline; Doxycycline hyclate; Antimicrobial therapy: co-trimoxazole or doxycycline; Doxycycline 100 mg capsules; Treatment with systemic therapy (doxycycline); Doxycycline hyclate ph.eur;   D00307
 D02129
 D03903
 D03904
 D07876 
 -   -   15件:
13,
23,
28,
46,
84,
85,
89,
96,
97,
158,
162,
167,
227,
280,
299
 25   Ergocalciferol  2件: Ergocalciferol; Ergocalciferol (vitamin d2);   D00187   1件: VDR   2件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption   5件:
46,
84,
96,
97,
299
 26   Ethambutol  1件: Ethambutol;   D00878
 D07925 
 -   -   2件:
84,
299
 27   Ethanol  14件: Endocannabinoid palmitoylethanolamide (pea); Palmitoylethanolamide; Treprostinil diethanolamine; Ut-15c (treprostinil diethanolamine); Ut-15c sr (treprostinil diethanolamine); Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel; Ethanolamine; Ethanolamine oleate;   D00068
 D02798
 D04855
 D06542 
 -   -   49件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
58,
61,
63,
64,
65,
66,
81,
84,
85,
86,
88,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
279,
280,
283,
284,
285,
288,
298,
299,
300,
331
 28   Florilglutamic acid F-18  0件:   -   -   -   1件:
84
 29   Fludeoxyglucose F-18  0件:   -   -   -   8件:
6,
13,
34,
46,
53,
84,
127,
300
 30   Folic acid  5件: Folic acid; Folic acid, vitamin b6, vitamin b12; Folic acid or folate; Rituximab, mtx, folic acid; Methotrexate and folic acid;   D00070   -   -   11件:
6,
13,
46,
49,
62,
84,
86,
96,
97,
254,
284
 31   Formaldehyde  0件:   D00017   -   -   1件:
84
 32   Golimumab  36件: Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Golimumab; Golimumab 100 mg; Golimumab 100 mg injections; Golimumab 2 mg/kg iv; Golimumab 50 mg; Golimumab 50 mg injections; Golimumab final vialed product (fvp); Golimumab intravenous; Golimumab intravenous (iv); Golimumab liquid in prefilled pen; Golimumab liquid in prefilled syringe; Golimumab liquid in vial; Golimumab pre-filled syringe; Iv golimumab; Sc golimumab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Exposure to golimumab; Golimumab (glm); Golimumab (optimization); Golimumab 1 mg per kg; Golimumab 2 mg per kg; Golimumab 200 mg; Golimumab 4 mg per kg; Golimumab 400 mg; Golimumab 50 mg in patients <80 kg and golimumab 100 mg in patients >80 kg; Golimumab dose 1; Golimumab dose 2; Golimumab prefilled syringe; Golimumab treatment optimization.; Simponi (golimumab); Simponi® (golimumab); Adalimumab, etanercept, golimumab or infliximab; Golimumab (cnto 148); Golimumab injection;   D04358   1件: TNF   9件: Adipocytokine signaling pathway, Apoptosis, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Inflammatory bowel disease (IBD), MAPK signaling pathway, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   5件:
46,
84,
96,
97,
271
 33   Heparin  7件: Heparin; Low molecular weight heparin calcium injection; Alkalinized lidocaine-heparin; Bladder instillation with heparin/ lidocaine; Heparin sodium; Heparin 25mg inhalation powder, hard capsule; Intralipid/heparin;   D07510   1件: SERPINC1   1件: Complement and coagulation cascades   11件:
60,
70,
79,
84,
107,
224,
226,
280,
299,
316,
317
 34   Hydroxychloroquine  16件: Hydroxychloroquine; Hydroxychloroquine sulfate; Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate-sulfasalazine-hydroxychloroquine; Sulphasalazine + hydroxychloroquine or prednisolone; Hydroxychloroquine (z0188); Hydroxychloroquine high; Hydroxychloroquine or chloroquine; Hydroxychloroquine reduced; Versus hydroxychloroquine; Hydroxychloroquine + prednisone; Sirolimus and hydroxychloroquine; Hydroxychloroquine higher dose; Hydroxychloroquine lower dose; Hydroxychloroquine sulphate;   D08050   -   -   18件:
13,
41,
46,
48,
49,
53,
56,
66,
84,
89,
90,
96,
222,
234,
254,
271,
298,
299
 35   Iloprost  21件: Iloprost; Iloprost injection, for intravenous use; Iloprost low dose; Iloprost sale di trometamolo; Iloprost therapy up to 2 ng/kg x min; Iloprost trometamol; Iloprost inhalation solution (ventavis); Aerosolized iloprost; Commercial ventavis® (iloprost); Iloprost (5 µg); Iloprost (ventavis bayq6256); Iloprost (ventavis inhaled, bayq6256); Iloprost (ventavis, bayq 6256); Iloprost (ventavis, bayq6256); Iloprost (ventavis®); Iloprost pd-15; Iloprost pd-6; Iloprost,(ventavis, bayq6256); Inhaled iloprost (ventavis, bayq6256); Ventavis (iloprost, bayq6256); Ventavis(iloprost);   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   4件:
51,
84,
85,
86
 36   Indium  5件: Indium; Indium 111-radiolabelled anti-cd66; Indium­ 111 ­labelled anti­-cd66; Indium-111 pentreotide; Indium-dtpa;   -   -   -   3件:
28,
84,
299
 37   Infliximab  66件: Infliximab; Infliximab [infliximab biosimilar 3]; Topical infliximab; Remicaide (infliximab); Abp 710 - biosimilar to infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 3 mg/kg; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-eu; Infliximab-pfizer; Innovator infliximab; Methotrexate + infliximab; Remicade (infliximab); Remicade® (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Intravitreal infliximab; 99m technetium infliximab; 99mtc-infliximab; Inflectra (infliximab); Adalimumab and infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Ct-p13 sc (infliximab); Infliximab (ifx alone); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab 20 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab-biosimilar; Infliximab-innovator; Cyclosporine vs infliximab; Infliximab (ifx); Adalimumab, etanercept, golimumab or infliximab; Infliximab (bcd-055); Infliximab and mtx;   D02598   1件: TNF   9件: Adipocytokine signaling pathway, Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), MAPK signaling pathway, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   23件:
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
85,
95,
96,
97,
98,
162,
164,
269,
271
 38   Iobenguane  0件:   D04559   -   -   1件:
84
 39   Isopropyl alcohol  0件:   D00137   -   -   10件:
13,
46,
58,
84,
96,
97,
269,
271,
279,
298
 40   L-Cysteine  1件: N-acetyl-cysteine;   D00026
 D02326 
 -   -   9件:
6,
13,
19,
84,
85,
88,
90,
254,
296
 41   Levofloxacin  2件: Levofloxacin; Mp-376 (levofloxacin solution for inhalation);   D00588
 D08120 
 -   -   2件:
84,
299
 42   Lidocaine  8件: Lidocaine; Local anesthesia (lidocaine hydrochloride); Lidocaine patch 5%; Lidocaine injection 2%; 5% lidocaine/5 mg/ml estradiol compound cream; Alkalinized lidocaine-heparin; Bladder instillation with heparin/ lidocaine; Lidocaine releasing intravesical system - liris®;   D00358
 D02086
 D08127 
 2件: SCN1A, SCN5A   2件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse   10件:
6,
13,
46,
84,
86,
97,
168,
226,
231,
256
 43   Maraviroc  2件: Maraviroc; All subjects will receive maraviroc 300mg orally twice a day for 6 weeks;   D06670   1件: CCR5   4件: Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human immunodeficiency virus 1 infection   2件:
46,
84
 44   Methionine  7件: Methionine; [11c]-methionine; C11-methionine; L-methionine; L-methionine ([11c]methyl); S-adenosyl-l-methionine; S-adenosyl-methionine (same) capsules;   D00019
 D04983 
 -   -   6件:
34,
75,
84,
93,
229,
300
 45   Methotrexate  81件: Methotrexate; Intrathecal methotrexate; Methotrexate treatment; Mycophenolate mofetil,methotrexate; Methotrexate 2.5 mg; Methotrexate 25 mg; Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Bms-582949 and methotrexate; Certolizumab pegol + methotrexate (mtx); Cp-690,550 + methotrexate; Etanercept + methotrexate; Etanercept , methotrexate; Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate as methotrexate disodium; Methotrexate capsules; Methotrexate disodium; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Oral methotrexate; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Methotrexate and folic acid; Methotrexate lachema 5inj. sol; Etanercept, methotrexate, prednisolone; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Azathioprine or methotrexate; Early immunosuppressants (azathioprine, methotrexate); Methotrexate bellon; Methotrexate bellon 25mg/ml; Clobetasol propionate + methotrexate; Treatment with systemic therapy (methotrexate); Cyclosporin, methotrexate (gvhd prophylaxis);   D00142
 D02115 
 2件: DHFR, DHFR2   2件: Folate biosynthesis, One carbon pool by folate   33件:
11,
13,
19,
34,
35,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
55,
56,
60,
62,
65,
84,
93,
96,
97,
162,
164,
172,
256,
271,
284,
285,
326,
331
 46   Methylphenidate  11件: Methylphenidate; Methylphenidate (mpd); Methylphenidate hydrochloride; Methylphenidate modified release; Methylphenidate modified release 20 mg; Methylphenidate modified release 30 mg; Methylphenidate modified release 40 mg; D-methylphenidate; Methylphenidate (overencapsulated); Methylphenidate 10mg tablets; Methylphenidate, fluoxetin, risperidone;   D01296
 D04999 
 2件: SLC6A2, SLC6A3   2件: Dopaminergic synapse, Synaptic vesicle cycle   7件:
6,
13,
34,
84,
113,
179,
206
 47   Methylprednisolone  29件: Methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methylprednisolone (drug); Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Methylprednisolone (or other glucocorticoid); Prednisone (and methylprednisolone); Infliximab, methylprednisolone, methotrexate; Methotrexate + methylprednisolone; Administration of rituximab and methylprednisolone; Methylprednisolone (mp); Corticosteroid treatment (methylprednisolone or prednisolone); Methylprednisolone or prednisolone; Methylprednisolone (mp) or prednisone (pred); Methylprednisolone mylan générique; Methylprednisolone pulse; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone or budesonide; Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Intravenous methylprednisolone; Intravenous (i.v.) methylprednisolone 1000 mg, total 9;   D00407
 D00751
 D00979
 D05000
 D05001
 D05002 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   36件:
2,
13,
25,
26,
35,
38,
39,
40,
41,
42,
43,
45,
46,
49,
50,
51,
60,
63,
64,
65,
66,
83,
84,
86,
96,
97,
145,
164,
220,
222,
224,
271,
283,
284,
285,
296
 48   Minocycline  7件: Minocycline; Glatiramer acetate with minocycline; Minocycline 100 mg film-coated tablets; Minocycline hydrochloride; Combination of minocycline and mtx or mtx alone; Lovastatin, then minocycline/lovastatin; Minocycline, then minocycline/lovastatin;   D00850
 D05045 
 -   -   14件:
2,
6,
8,
13,
46,
84,
85,
90,
94,
162,
201,
206,
280,
299
 49   Mycophenolic acid  2件: Mycophenolic acid; Mycophenolic acid mofetil;   D05096   2件: IMPDH1, IMPDH2   1件: Purine metabolism   34件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
84,
85,
95,
96,
162,
164,
222,
224,
226,
228,
234,
283,
284,
285,
300
 50   Nicotine  9件: Nicotine; Nicotine gum; Nicotine nasal spray 10 mg/ml (0.5 mg/spray); Nicotine patch; Nicotine transdermal patch; Nicotinell; Nicotinell 17,5 mg/24-stunden-pflaster; Nicotinell 35 mg/24-stunden-pflaster; Transdermal nicotine;   D03365
 D05156
 D05157 
 16件: CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG   3件: Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction   2件:
6,
84
 51   Octreotide  5件: Octreotide; Octreotide lar; Octreotide-lar; Gallium-68-dota-n-octreotide; Octreotide lar / sandostatin lar (lar=long acting release);   D00442
 D06495 
 1件: SSTR2   3件: Gastric acid secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway   8件:
67,
75,
84,
85,
89,
96,
193,
227
 52   Oxygen  10件: Oxygen; Oxygen 40 %; Nitric oxide plus oxygen; Oxygen supplementation; Continuous oxygen; Medical air vs oxygen; Maternal hyperoxygenation; Medical grade oxygen; Perfluorinated gas/oxygen mixture; Helium / oxygen mixed gas inhalation therapy;   D00003   -   -   18件:
5,
6,
17,
46,
49,
70,
84,
85,
86,
88,
90,
96,
97,
193,
211,
226,
299,
330
 53   Oyster  2件: Fermented oyster extract; Oyster;   -   -   -   1件:
84
 54   Pentoxifylline  1件: Pentoxifylline;   D00501   -   -   10件:
26,
56,
84,
93,
96,
113,
220,
222,
296,
298
 55   Pirfenidone  6件: Pirfenidone; Pirfenidone and nintedanib; Pirfenidone or nintedanib; Pirfenidoneone; Sub-study: pirfenidone; Pirfenidone 267 mg [esbriet];   D01583   6件: CCL2, IL10, IL1A, IL1B, IL6, TNF   5件: Cellular senescence, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, TGF-beta signaling pathway, TNF signaling pathway   10件:
34,
46,
50,
51,
58,
84,
85,
164,
222,
228
 56   Prednisolone  74件: Prednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methyloprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Peg-liposomal prednisolone sodium phosphate; Prednisolone sodium phosphate; Prednisone/prednisolone; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Intravenous methyl prednisolone; Methyl prednisolone; Methylprednisolone (or other glucocorticoid); Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; Infliximab, methylprednisolone, methotrexate; Long-circulating liposomal prednisolone; Methotrexate + methylprednisolone; Methotrexate - etanercept - prednisolone arm; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Prednisolone & dipyridamole; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).; Corticosteroids (prednisone or prednisolone); Oral prednisolone; Administration of rituximab and methylprednisolone; Prednisolone and taper; Etanercept, methotrexate, prednisolone; Methylprednisolone (mp); Prednisolone + mabthera; Corticosteroid treatment (methylprednisolone or prednisolone); Methylprednisolone or prednisolone; Methylprednisolone (mp) or prednisone (pred); Methylprednisolone mylan générique; Methylprednisolone pulse; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Prednisone or prednisolone; Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Prednisolone 1mg tablets; Prednisolone 5mg tablet; Glucocorticoid (prednisone or prednisolone); Low dose prednisolone; Medium dose prednisolone; Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Corticosteroid (prednisolone); Prednisolone sodium succinate; Methylprednisolone or budesonide; Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisolone sodium metasulphobenzoate; Prednisolone tablets b.p. 5mg; Intravenous methylprednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil;   D00472
 D00980
 D00981
 D00982
 D01239
 D01998
 D02156
 D03301 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   38件:
11,
13,
25,
26,
35,
38,
39,
41,
43,
44,
45,
46,
49,
50,
51,
56,
60,
61,
63,
64,
65,
66,
75,
81,
84,
85,
95,
96,
97,
113,
145,
162,
222,
269,
271,
296,
299,
300
 57   Prednisone  59件: Prednisone; Prednisone - azathioprine; Prednisone alone; Granulocyte-colony stimulating factor (g-csf) and prednisone; Prednisone/prednisolone; Prednisone acetate; Prednisone, cyclophosphamide; Over encapsulated prednisone; Prednisone and ustekinumab treatment; Prednisone capsules; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Prednisone (and methylprednisolone); 0 mg prednisone; 5 mg prednisone; Methylprednisone; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Rayos (delayed-release prednisone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide-prednisone-azathioprine; Oral prednisone 5mg; Prednisone discontinuation; Chinese herb prescription granule plus prednisone; Enalapril valsartan methylprednisone; Hormone (prednisone); Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Prednisone + inhibace/cozaar; Prednisone and cyclophosphamide; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Glucocorticoid (prednisone or prednisolone); Hydroxychloroquine + prednisone; Azathioprine/prednisone; 5-asa, prednisone, azathioprine or remicade; 5-aminosalicylic acid(5-asa) and/or prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone); Prednisone 0,5 mg/kg orally on alternate days; Prednisone, fk506, mmf; Tacrolimus combined with prednisone; Prednisone acetate tablets; Oral prednisone; Sotatercept with prednisone boost; Prednisone and mycophenolate mofetil; Thalidomide, cyclophosphamide and prednisone;   D00473   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   44件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331
 58   Propofol  3件: Propofol; Propofol-lipuro; Intubated with propofol (ip);   D00549   16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ   2件: GABAergic synapse, Neuroactive ligand-receptor interaction   8件:
6,
21,
22,
34,
46,
84,
98,
296
 59   Quercetin  3件: Quercetin; Dasatinib + quercetin; Quercetin (dietary supplement);   -   -   -   5件:
84,
85,
192,
285,
299
 60   Rifampicin  1件: Rifampicin;   D00211   -   -   7件:
6,
13,
17,
46,
84,
86,
299
 61   Riociguat  12件: Riociguat; Riociguat (adempas, bay63-2521); Riociguat coated tablet 0.5 mg; Riociguat coated tablet 1.0 mg; Riociguat coated tablet 1.5 mg; Riociguat coated tablet 2.0 mg; Riociguat coated tablet 2.5 mg; Adempas (riociguat, bay63-2521); Riociguat (bay63-2521); Riociguat granules 0.3% for oral application; Riociguat oral product; Riociguat pill;   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   2件: Platelet activation, Vascular smooth muscle contraction   6件:
51,
84,
86,
88,
225,
299
 62   Rituximab  52件: Rituximab; Rituximab (rituxan); Mabthera (rituximab); Mabthera or biosimilar rituximab product; Rituximab infusion; Rituximab it; Rituximab iv; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Rituximab (mabthera® or rituxan®).; Rituximab and cyclophosphamide iv; Rituximab (arm a); Rituximab (arm b); Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Rituxan (inn: rituximab), brand name in the united states; Rituxan® (rituximab); Rituximab - mabthera; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab mabthera; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Sait101 (proposed rituximab biosimilar); Individualized dose of rituximab; Rituxan (rituximab); Standard dose of rituximab; Administration of rituximab and methylprednisolone; Rituximab (anti-cd20); Alemtuzumab and rituximab; Bendamustine, rituximab; Mabthera or biosimilar rituximab; Rituximab (mabthera®); Alemtuzumab, rituximab; Dexamethasone and rituximab; Rhtpo in combination with rituximab; Immunosuppressive treatment (eg, rituximab); Rituximab (rtx) and azathioprine (aza); Intravenous rituximab; Combined plasma exchange (pex), rituximab, and corticosteroids; The standard steroid treatment, plasma exchange and rituximab; Rituximab 1g iv; Rituximab combined with omalizumab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Rituximab/ mabthera; Rituximab or rituximab hyaluronidase human;   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   42件:
11,
13,
14,
17,
35,
36,
43,
44,
45,
46,
49,
50,
51,
52,
53,
56,
60,
61,
63,
64,
65,
66,
83,
84,
85,
86,
93,
94,
96,
97,
162,
222,
223,
229,
256,
271,
283,
284,
285,
288,
300,
331
 63   Roflumilast  2件: Roflumilast; Oral roflumilast;   D05744   4件: PDE4A, PDE4B, PDE4C, PDE4D   1件: cAMP signaling pathway   2件:
84,
299
 64   Rubidium  1件: Rubidium;   -   -   -   1件:
84
 65   Sarilumab  4件: Sarilumab; Sarilumab sar153191; Sarilumab sar153191 (regn88); Sarilumab 200 mg/1.14 ml subcutaneous solution [kevzara]_#1;   D10161   1件: IL6R   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   5件:
41,
46,
84,
107,
271
 66   Selexipag  4件: Selexipag; I.v. selexipag; Oral selexipag (uptravi); Selexipag (uptravi);   D09994   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   5件:
51,
70,
84,
86,
88
 67   Tadalafil  11件: Tadalafil; Tadalafil and ambrisentan upfront combination therapy; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Fdc macitentan/tadalafil; Tadalafil 20 mg film-coated tablets; Tadalafil 40 mg; Tadalafil oral suspension; Tadalafil, placebo; Tadalafil- tablet or oral suspension; Tadalafil 20 mg; Tadalafil and sildenafil;   D02008   1件: PDE5A   1件: Purine metabolism   6件:
6,
51,
75,
84,
86,
113
 68   Thalidomide  9件: Thalidomide; Thalidomide (drug); Fpf 300 (thalidomide); Melphalan, thalidomide and dexamethasone; Thalidomide pharmion; Thalidomide celgene - 50 mg capsula rigida - uso orale - blister (pvc/pe/aclar/alu) 28 capsule; Thalidomide 100mg; Thalidomide 150mg; Thalidomide, cyclophosphamide and prednisone;   D00754   1件: TNF   4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, NF-kappa B signaling pathway, TNF signaling pathway   18件:
2,
16,
20,
28,
49,
51,
53,
65,
84,
85,
94,
96,
97,
227,
271,
280,
298,
331
 69   Tofacitinib  23件: Chong kun dang tofacitinib tablet; Cp-690,550 (tofacitinib); Tofacitinib; Tofacitinib (xeljanz); Tofacitinib 5 mg; Tofacitinib 5 mg [xeljanz]; Tofacitinib 5mg po bid; Tofacitinib citrate; Tofacitinib citrate (clinical trial image); Tofacitinib citrate (commercial image); Tofacitinib citrate cp-690550; Tofacitinib with methotrexate; Tofacitinib without methotrexate; Tofacitinib/baricitinib; Tofacitinib 5 mg twice daily; Tofacitinib 5mg [xeljanz] 1 year open-label extension; Tofacitinib 5mg oral tablet [xeljanz] 16 week trial; 15n2-tofacitinib; Tofacitinib citrate (proposed commercial formulation – debossed); In double-blind phase: treatment with tofacitinib; In open-label phase: treatment with tofacitinib; Tofacitinib 10 mg; Tofacitinib 2 mg;   D09970   4件: JAK1, JAK2, JAK3, TYK2   2件: Chemokine signaling pathway, JAK-STAT signaling pathway   9件:
46,
49,
50,
51,
84,
96,
97,
107,
271
 70   Tranilast  1件: Tranilast;   D02027   -   -   4件:
46,
84,
106,
113
 71   Treprostinil  32件: Iontophoresis of treprostinil; Oral treprostinil; Treprostinil; Treprostinil diethanolamine; Inhaled treprostinil; Treprostinil sodium for inhalation; Eutonic treprostinil solution; Hypotonictreprostinil solution; Inhaled dry powder treprostinil (liq861); Intravenous treprostinil; Intravenous/subcutaneous treprostinil; Liq861 inhaled treprostinil; Oral treprostinil (ut-15c) sustained release tablets; Parenteral remodulin (treprostinil) injection; Rapid dose titration group of subcutaneous treprostinil; Remodulin (treprostinil sodium); Remodulin® (treprostinil) 1 mg/ml solution for infusion; Remodulin® (treprostinil) 10 mg/ml solution for infusion; Remodulin® (treprostinil) 2.5 mg/ml solution for infusion; Remodulin® (treprostinil) 5 mg/ml solution for infusion; Slow dose titration group of subcutaneous treprostinil; Subcutaneous treprostinil; Treprostinil diolamine; Treprostinil inhalation powder; Treprostinil inhalations; Treprostinil injectable product; Treprostinil sodium; Treprostinil sodium solution for inhalation; Treprostinil sodium, ut-15; Treprostinil, ut-15, lrx-15, 15au81, bw a15au, u-62, 840; Ut-15c (treprostinil diethanolamine); Ut-15c sr (treprostinil diethanolamine);   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   5件:
51,
84,
85,
86,
88
 72   Ursodeoxycholic acid  13件: Ursodeoxycholic acid; Tauroursodeoxycholic acid; Tauroursodeoxycholic acid capsules; Udca (ursodeoxycholic acid); Ursodeoxycholic acid (urso); Ursodeoxycholic acid 300mg capsule; Ursodeoxycholic acid 300mg tablet; Ursodeoxycholic acid capsules; Ursodeoxycholic acid combination of immunosuppressive agents; Norursodeoxycholic acid; Ursodeoxycholic acid (udca); Tauroursoursodeoxycholic acid, brand name tudcabil; Ursodiol (ursodeoxycholic acid, udca);   D00734   1件: NR1H4   1件: Bile secretion   12件:
6,
8,
20,
67,
84,
93,
94,
95,
96,
97,
234,
299
 73   Ustekinumab  32件: Ustekinumab; Prednisone and ustekinumab treatment; Ustekinumab (approximately 6 mg/kg); Ustekinumab 90 milligram (mg); Ustekinumab iv; Ustekinumab sc; Ustekinumab 6 mg/kg; Ustekinumab 90 mg; Subcutaneous ustekinumab; Stelara (ustekinumab); Ustekinumab liquid in prefilled syringe; Ustekinumab 180 mg; Ustekinumab 45 mg; Evaluation of biological predictive factors of clinical response to ustekinumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Placebo ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab 130 mg iv; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab approximately 6 mg/kg (iv); Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab sc injection;   D09214   3件: IL12A, IL12B, IL23A   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   16件:
13,
37,
41,
46,
49,
50,
53,
56,
65,
84,
93,
96,
97,
162,
269,
271
 74   Water  13件: 5% glucose water solution; Water; Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; 15 o water; Water for injection; 15-o labeled water; Pl 12185/0002 & pl 12185/0005(water for injection); Dextrose, 5% in water; High water intake; Lactose in water; Water for injections; Water for injections, ep;   D00001   -   -   22件:
2,
5,
6,
13,
17,
19,
28,
35,
46,
53,
57,
63,
65,
67,
78,
84,
97,
193,
226,
271,
278,
299

先頭へ